Meaning Strategies to detect and target multiple coexistent resistance mechanisms will be needed to achieve more durable control of drug resistance in EGFR-mutant lung cancer.Abstract Importance Osimertinib mesylate is used globally to treat EGFR-mutant non–small cell lung cancer (NSCLC) with tyrosine...
Meaning At current costs, by World Health Organization cost-effectiveness threshold criteria, osimertinib is not cost-effective as a first-line therapy of EGFR-mutated NSCLC. Abstract Importance The survival of patients with advanced non–small cell lung cancer (NSCLC) with epidermal growth factor rec...
Despite these challenges, wider adoption of recommendation approaches holds plenty of opportunities to support and accelerate biological research. To illustrate this point, in this study we focused on the problem of drug resistance in lung cancer. Our goal was to build a recommendation solution that ...
Osimertinib and chemotherapy provide similar OS benefits in patients with T790M-positive tumors.#Different prognostic meaning of tumor resistant gene detected from tumor or blood in patients with EGFR-mutant lung cancer#The study demonstrates that patients with EGFR-mutant lung can...
Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study aimed to examine anlotinib plus icotinib as a first-line treatment option for advanced NSCLC carrying EGFR mutation with or without concurrent ...
Epidermal growth factor receptor (EGFR) mutations are strong determinants of tumour response to EGFR tyrosine kinase inhibitors in non-small-cell lung cancer (NSCLC). Pleural effusion is a common complication of lung cancer. In this study, we assessed th
“When we studied the tumor results on patients who were T790M-negative in the blood we could differentiate those who do better or worse on osimertinib, meaning that a biopsy is an effective fall back to clarify who should and who shouldn't get the drug,” said Oxnard. “We conclude that...
AThe IC50 you obtain refers to the cell proliferation inhibition assay (half maximal inhibitory concentration), which is different in meaning from the IC50 on our website. The IC50 often refers to the inhibition rate of the target without cell experiments, which is generally determined through kina...
Meaning Ivonescimab plus chemotherapy significantly improved progression-free survival with tolerable safety profile in patients with non–small cell lung cancer who previously underwent EGFR-TKI treatment and may offer a new treatment option for patients with TKI resistance. Abstract Importance For pat...
Meaning The findings of this randomized clinical trial suggest that gefitinib plus chemotherapy may be a viable first-line treatment for patients with brain metastases associated with EGFR-mutant NSCLC. Abstract Importance Use of tyrosine kinase inhibitors (TKIs) is the standard therapy for epidermal gr...